Comparison of currently licensed rotavirus vaccines

VaccineaParent strain and genotypeFormulationDose regimen% Protection against severe rotavirus infectionb% Reduction in hospitalizationAssociation with intussusception% Vaccine virus shedding
RotaTeqBovine rotavirus strain WC3, P7[5]G65 reassortants; 4 reassortants with the VP7gene from G1, G2, G3, or G4 and 1 reassortant with the VP4 P1A[8] gene from the human rotavirus parent strain with the remainder of the genes from the WC3 bovine rotavirus parent3 oral doses at 2, 4, and 6 mo of age9863No9
RotarixHuman rotavirus strain 89-12, P1A[8]G1No reassortants; RIX4414, a further-passaged human rotavirus 89-12 strain2 oral doses at 2 and 4 mo of age8542No<50
  • a RotaTeq, a pentavalent vaccine, is manufactured by Merck. Rotarix, a monovalent vaccine, is manufactured by GlaxoSmithKline.

  • b Different scoring systems were used; therefore, these results are not comparable.